Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis
Abstract Background Genetic testing is moving from targeted investigations of monogenetic diseases to broader testing that may provide more information. For example, recent health economic studies of genetic testing for an increased risk of breast cancer suggest that it is associated with higher cos...
Main Authors: | Erik Gustavsson, Giovanni Galvis, Niklas Juth |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | BMC Medical Ethics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12910-020-00545-8 |
Similar Items
-
Next-Generation Sequencing in Order to Better Characterize a BRCA Variant of Uncertain Significance
by: Steven Sorscher, et al.
Published: (2017-07-01) -
Federated analysis of BRCA1 and BRCA2 variation in a Japanese cohort
by: James Casaletto, et al.
Published: (2022-03-01) -
Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics
by: Corinna Ernst, et al.
Published: (2018-03-01) -
How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
by: Ava Kwong, et al.
Published: (2022-05-01) -
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
by: Daniele Fanale, et al.
Published: (2021-06-01)